Immunome, Inc.

NasdaqCM IMNM

Immunome, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD 214.91 M

Immunome, Inc. Shareholders' Equity is USD 214.91 M for the quarter ending September 30, 2024, a 3,436.97% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Immunome, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 6.08 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: IMNM

Immunome, Inc.

CEO	Dr. Clay B. Siegall Ph.D.
IPO Date	Oct. 2, 2020
Location	United States
Headquarters	665 Stockton Drive
Employees	55
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Key trends

Past 5 years